REG - Oxford Biomedica PLC - Lucinda Crabtree joins OXB as CFO today

Oxford BioMedicaAnnouncement

02/09/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240902:nRSB4180Ca&default-theme=true

RNS Number : 4180C  Oxford Biomedica PLC  02 September 2024

 

 

 

Lucinda Crabtree joins Oxford Biomedica as Chief Financial Officer today

Oxford, UK - 2 September 2024: Oxford Biomedica plc (LSE:OXB) ("Oxford
Biomedica", "OXB" or "the Company"), a quality and innovation-led cell and
gene therapy CDMO, announces that Lucinda (Lucy) Crabtree Ph.D. has today
joined Oxford Biomedica as Chief Financial Officer (CFO) and board member.
Lucinda's appointment was previously announced
(https://www.londonstockexchange.com/news-article/OXB/oxb-announces-cfo-transition/16571605)
on 17 July 2024.

Lucinda Crabtree was previously at MorphoSys AG where she served as CFO,
leading a finance team across the US and Germany until the company's
acquisition by Novartis. Previously, she was CFO at Autolus Therapeutics, a
Nasdaq listed clinical stage biopharmaceutical company. Lucinda also brings
extensive experience from the investment and banking sectors, having held
roles at institutions including Woodford Investment Management, Goldman Sachs,
and Jefferies.

 

Dr. Frank Mathias, Chief Executive Officer of Oxford Biomedica, commented: "We
are thrilled that Lucy has joined Oxford Biomedica as our new CFO and Board
member today. Lucy brings a wealth of experience from her roles as a CFO and
time as a healthcare investor and equity research analyst. Her experience will
be invaluable as we grow our international position as a leading cell and gene
therapy CDMO."

 

Lucinda Crabtree, Chief Financial Officer of Oxford Biomedica said: "I am
excited to be joining Oxford Biomedica as CFO today. I firmly believe in the
Company's growth strategy and am looking forward to working with the Board and
the rest of the leadership team. Together, I'm confident we will fulfil our
mission of enabling our growing client base to deliver life-changing therapies
to patients."

 

-Ends-

 

Enquiries:

 

Oxford Biomedica plc:

Sophia Bolhassan, Head of Investor Relations - T: +44 (0) 1865 509 737 / E:
ir@oxb.com

 

ICR Consilium:

T: +44 (0)20 3709 5700 / E: oxfordbiomedica@icrhealthcare.com

Mary-Jane Elliott / Angela Gray / Davide Salvi

 

 

About Oxford Biomedica

 

Oxford Biomedica (LSE: OXB) is a quality and innovation-led contract
development and manufacturing organisation (CDMO) in cell and gene therapy
with a mission to enable its clients to deliver life changing therapies to
patients around the world.

 

One of the original pioneers in cell and gene therapy, OXB has more than 25
years of experience in viral vectors; the driving force behind the majority of
cell and gene therapies. OXB collaborates with some of the world's most
innovative pharmaceutical and biotechnology companies, providing viral vector
development and manufacturing expertise in lentivirus, adeno-associated virus
(AAV), adenovirus, and other viral vector types. Oxford Biomedica's
world-class capabilities span from early-stage development to
commercialisation. These capabilities are supported by robust
quality-assurance systems, analytical methods and depth of regulatory
expertise.

 

OXB offers a vast number of unique technologies for viral vector
manufacturing, including a 4th generation lentiviral vector system (the
Tetravecta(TM) system), dual plasmid system for AAV production, suspension and
perfusion process using process enhancers and stable producer and packaging
cell lines.

 

Oxford Biomedica, a FTSE4Good constituent, is headquartered in Oxford, UK. It
has bioprocessing and manufacturing facilities across Oxfordshire, UK, Lyon
and Strasbourg, France, and near Boston, MA, US. Learn more at www.
(https://www.oxb.com/) oxb.com (https://www.oxb.com/) , and follow us
on LinkedIn (https://www.linkedin.com/company/oxford-biomedica/)
 and YouTube (https://www.youtube.com/user/OxfordBioMedica) .

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOAEAPNFELXLEFA